AbbVie’s Orilissa gets FDA nod as Humira competition loomsAbbVie needs new drugs as its mega-blockbuster Humira won’t bring in billions forever – and after the embarrassing Share XAbbVie’s Orilissa gets FDA nod as Humira competition loomshttps://pharmaphorum.com/news/abbvies-orlissa-gets-fda-nod-as-humira-competition-looms/
Forendo joins race to develop endometriosis drugsFinland’s Forendo Pharma is beginning early-stage trials of a potential new treatment for endometriosis, joining a gang of Share XForendo joins race to develop endometriosis drugshttps://pharmaphorum.com/news/forendo-joins-race-to-develop-endometriosis-drugs/
AbbVie’s elagolix shows promise in uterine fibroids treatmentAbbVie’s elagolix has shown promise in a phase 2 trial in women with uterine fibroids, a second indication for Share XAbbVie’s elagolix shows promise in uterine fibroids treatmenthttps://pharmaphorum.com/news/abbvies-elagloix-shows-promise-uterine-fibroids-treatment/
